- Home
- PLRX vs GANX Comparison
PLRX vs GANX Comparison
Compare PLRX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- GANX
- Stock Information
- Founded
- PLRX 2015
- GANX 2017
- Country
- PLRX United States
- GANX United States
- Employees
- PLRX N/A
- GANX N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- GANX Health Care
- Exchange
- PLRX Nasdaq
- GANX Nasdaq
- Market Cap
- PLRX 93.3M
- GANX 79.8M
- IPO Year
- PLRX 2020
- GANX 2021
- Fundamental
- Price
- PLRX $1.61
- GANX $1.96
- Analyst Decision
- PLRX Hold
- GANX Strong Buy
- Analyst Count
- PLRX 11
- GANX 6
- Target Price
- PLRX $3.79
- GANX $8.00
- AVG Volume (30 Days)
- PLRX 973.1K
- GANX 727.4K
- Earning Date
- PLRX 11-06-2025
- GANX 11-12-2025
- Dividend Yield
- PLRX N/A
- GANX N/A
- EPS Growth
- PLRX N/A
- GANX N/A
- EPS
- PLRX N/A
- GANX N/A
- Revenue
- PLRX N/A
- GANX N/A
- Revenue This Year
- PLRX N/A
- GANX N/A
- Revenue Next Year
- PLRX N/A
- GANX N/A
- P/E Ratio
- PLRX N/A
- GANX N/A
- Revenue Growth
- PLRX N/A
- GANX N/A
- 52 Week Low
- PLRX $1.10
- GANX $1.41
- 52 Week High
- PLRX $15.88
- GANX $2.81
- Technical
- Relative Strength Index (RSI)
- PLRX 47.40
- GANX 53.06
- Support Level
- PLRX $1.61
- GANX $1.66
- Resistance Level
- PLRX $1.72
- GANX $2.04
- Average True Range (ATR)
- PLRX 0.13
- GANX 0.15
- MACD
- PLRX -0.02
- GANX -0.01
- Stochastic Oscillator
- PLRX 29.00
- GANX 64.13
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.